Symbiosis Pharmaceutical Services has expanded its quality control laboratory in Stirling with the installation of a new 30°C stability chamber to strengthen its drug product stability testing capabilities.

The CDMO said the addition enables it to replicate all four ICH-defined climatic zones, supporting assessment of injectable drug products under a full range of global storage conditions.

The upgrade is intended to support commercial supply activities by improving confidence in product stability across different environmental conditions relevant to international distribution.

Symbiosis operates a QC laboratory that was commissioned in 2023, which it uses to support analytical testing for client programmes and to streamline the transition from development through manufacturing to release.

The company said the new chamber complements its existing stability storage range, which includes conditions at -80°C, -20°C, 5°C, 25°C and 40°C, aligned with ICH Q1A(R2) guidelines.

Joanne Anderson, chief commercial officer at Symbiosis, said: “The addition of our new 30°C stability storage capability marks another important stage in the expansion of Symbiosis commercial drug product supply services.”

She added that growing global demand for sterile drug products requires robust stability testing across multiple climatic zones to support supply to international markets.

The investment forms part of wider efforts by Symbiosis to expand its integrated manufacturing and analytical services for biotechnology and pharmaceutical partners.

The company specialises in the GMP manufacture of sterile injectable drug products and provides development and manufacturing support for clinical and commercial supply chains.